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Abstract
Background: Sentinel lymph node (SLN) mapping and biopsy have become the standard of care
for axillary staging of a breast cancer patient. Higher rate of use has led to the identification of an
absolute failure rate and a subset of patients who fail lymph node mapping due to causes
independent of the procedure. Failure of lymph node mapping leads to more invasive procedures
with higher morbidity. Body mass index has been associated with higher SLN failure rate.

Methods: Retrospective study of patients who underwent Sentinel lymph node procedures
between October 2003 to June 2008 at University of New Mexico. After internal board review,
electronic medical database was used to identify patients within study parameters, and to collect
data needed for BMI calculation and SLN procedure details.

Results: BMI of greater than 30 had a failure rate of 44.83% with blue dye and 13.33% with
technetium collide tracer (p value 0.05 and 0.04). BMI less than 30 had a failure rate of 30.56%
for blue dye and 4.63 for technetium. Odds of success for blue dye were 0.5 and 0.3 for
technetium for patients with BMI greater than 30. Failure rates for palpation of sentinel node
41.47% and 50% for BMI less than 30 and greater than 30 respectively.

Discussion: Study identified higher failure rate in obese patients compared to overweight to
normal weight patients. Study indicates higher failure rates in obese patients than the reported
absolute failure rate of SLN mapping.

Conclusion: Obesity increases the failure rate of both blue dye and technetium colloid. Obesity
does not contribute to the failure to palpate a sentinel node. Obesity alone is not a
contraindication for SLN mapping suing Technetium or blue dye, but surgeon must be aware of
higher failure rate in obese patients and change their procedural methods to accommodate.

Introduction
Axillary staging is important because it influences overall staging and future decisions
regarding adjuvant treatments. However, Axillary dissection can lead to significant side effects,
such as lymphedema, nerve injury, chronic pain, neuromas, seroma formation, and increase
susceptibility to infections.1Further, self-breast exams, screening mammography and access to
good healthcare maintenance have led to a decrease in the number of advanced invasive breast
cancers that involve the lymph node basins. Therefore, those patients who are early stage and/or
without detectable lymph node involvement will not clinically benefit from an axillary lymph
node dissection, but may suffer the adverse effects.1-3
A sentinel lymph node is defined as the first lymph node or nodes to which a cancer
might metastasize from the primary tumor. In order to identify the sentinel lymph node(s), the
surgeon injects a radioactive substance (technetium sulfur-labeled colloid) and/or blue dye
peritumorally or in the subareolar/dermal lymphatic plexus.2Once the SLN is located, the
surgeon removes the lymph node(s). In addition to a decrease in morbidity, SLNB procedures
have reported successful lymph node identification rates between 65%-94%

2, 4

with false

negative rates between 0%-11% and an absolute failure rate that has been reported to be between
1% to 2%. 1, 2, 5, 6The efficacy of sentinel lymph node identification is reported as 94% using
Isosulfan blue dye technique. 4
Many factors have been associated with SLNB mapping failure. For example, injection
methods, inadequate volume of tracer, dispersion of the tracer, and time of massage are
considered as extrinsic factors that may influence the ability of the mapping dyes or colloids to
reach the lymphatic basin. In addition, inflammation around the biopsy site, compression of the
lymhatics by the tumor, affects of neoadjuvant chemotherapy treatments, localized edema dye to

blue dye allergy, and other issues such as degree of fatty tissue content have been postulated as
possible causes for the failure of SLNB7-9. A potential serious side-effect of blue dye injection is
the possibility of severe anaphylactic allergic reaction at the rate of about 0.7% to 1.9% among
patient who undergo SLNB

5, 10-12

. In addition, there are observed corollaries which hypothesize

that complete replacement of lymph node by tumor cells can hinder dye or colloid penetration
into the lymph node that may contribute to failure of proper lymph mapping. Lymph congestion
by tumor cells hypothesis has been made largely by observing large dilated lymphatic channels
that terminate abruptly at lymph glands later found to be completely replaced by tumor.
Furthermore, even with surgeons experienced in SNLB procedure and progressive accumulation
of procedural knowledge, there still remains an absolute failure rate that indicates there might be
inherent patient factors that contribute to lymphatic mapping failure in a subset of the patients.
Identifying this subset of patients ahead of time can potentially benefit the patient by foregoing a
lengthy sampling procedure that may lead to increased operative time and/or yield poor quality
information in this particular population. Identifying a group of patients who specifically fail to
demonstrate blue dye as a means of sentinel lymph node detection can allow this group of
patients to forgo exposure to an additional potential allergen that can have serious side effects in
some patients.
It is important to identify factors that contribute to the failure of the SLNB procedure, as
this can add operative time to a patient’s procedure and expose them to potential serious
allergens with the use of vital blue dyes. Recent data on SNLB procedural outcomes shows that
with an increased use of SLNB procedure, the rate of failure has increased reflexively
addition, various side effects, such as anaphylactic reactions,
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interference with pulse

oximeter12, and adverse skin reactions14 rates will become more prominent. If it is possible to

identify the subset of patients or characteristics in patients that would correlate to a higher degree
of failure, surgical oncologists may be able to avoid subjecting patients to unnecessary
procedures and better inform the patients of the benefits versus the drawbacks, which will help
promote the autonomy of the patient and increase the overall quality of care that is offered.
We believe that there is a subgroup of breast cancer patients in whom Technetium or blue
dyes are unlikely to be efficacious in determining accurate sentinel nodes using standard SLNB
techniques. If we can reproducibly identify these patients with preoperative screening criteria,
we can potentially save these patients’ increased length in operative time and exposure to
possible severe allergens.18, 19 Our main objective is to retrospectively investigate the failure rates
of SLNB patients who used blue dye with a BMI greater than 30. SNLB procedural outcomes
will be ascertained compared to reported “absolute” failure rate to see if there is a statistically
significant difference between our population of interest and reported absolute failure rates with
respect to the blue dye, technetium, and the ability of the surgeon to palpate a sentinel node.

Methods
A retrospective review will be conducted of female breast cancer patients who underwent
lymphatic mapping for sentinel node biopsy at the University of New Mexico Hospital from Sep
2003 to June 2008. The data was captured in the University of New Mexico Main Operating
Room and Outpatient Surgery and Imaging Services (OSIS) Operating Room operative log
database. All patients eligible for our study include those who (1) are female; (2) were 18 years
of age or older at the time of treatment; (3) required surgical treatment for diagnosed or
suspected invasive malignant breast cancer and also required axillary staging as part of their
standard of care treatment, and/or had elected to have therapeutic mastectomy for DCIS, and/or
prophylactic mastectomy due to risk factors and had risk of occult invasive malignancy. Patients

who were pregnant or who did not qualify for SLNB under current National Comprehensive
Cancer Network (NCCN) treatment guidelines were excluded from the study.
Lymphatic mapping and SLNB were performed at UNM Hospital or OSIS in the
standard fashion by surgeons who had met the usual required training and experience with SLNB
techniques. Lymph nodes were considered sentinel nodes if they met the following criteria either
alone or in combination: (1) blue stained, (2) had a blue lymphatic leading up to the node, (3)
had a 10:1 ex vivo ratio of colloid uptake, or (4) were palpable. The axilla was carefully
examined at the end of the SLNB procedure, and any additional lymph nodes that were palpable
were also removed and sent as additional sentinel nodes. The characteristics of the sentinel nodes
were collected from dictated procedure note, operation work sheet, and the finalized pathology
report. The data will be used to determine the failure rates between patients whose BMI is less
than 30 to patients with BMI greater than 30. The rates will then be compared to reported
absolute failure rate to determine if a higher BMI corresponds with higher failure rate in sentinel
lymph node mapping.

Results
Search of University of New Mexico electronic medical data base during the period of
September 2003 to June 25, 2008 yielded 560 entries. From the 560 possible entries 198
individual patient records were identified that fit the study parameters. Entries that were rejected
were largely due to patient record duplication and Sentinel node mapping other than breast (i.e.
skin). Patient age ranged from 24 to 84 with mean age of 55. BMI ranged from 17 to 47 with
mean BMI of 29. The ethnic distribution among the patient population reflected Caucasian and
Hispanic predominance (Table 1).

Figure 1 shows the success and failure rates of sentinel node identification using blue
dye, radioactive tracer and palpation for patients with BMI less than 30 and BMI greater than 30.
Our analysis showed that patients who have a BMI less than 30 showed a SLN mapping failure
by blue dye to be 30.56% while patient with BMI greater than 30 showed a failure rate of
44.83%. The failure rate showed to be marginally significant with p value of 0.05. The patients
with BMI of greater than 30 seem more likely to fail with 0.5 odds of success (table 2).
Technetium use showed a failure rate of 4.63% in patients with BMI of less than 30, however,
showed a failure rate of 13.33% with failure rate difference being statistically significant (p =
0.0404). The odds of a surgeon finding a hot node with success with the use of technetium tracer
in a patient with BMI greater than 30 were shown to be 0.3 (table 2).
The failure of the surgeon to palpate a sentinel node is 41.47% and 50% in patients
whose BMI is less than 30 and greater than 30 respectively. The difference in rates is statistically
insignificant (p = 0.2547). The odds of success to palpate seem likely to fail with the odds of
success of 0.7. Table 2 shows as the BMI cut off increases from 25 to 30 the efficacy of the
tracer to detect a sentinel node decreases on all three detection methods.

Discussion
Patients’ BMI has been considered to be a risk factor for development of breast
carcinoma. Further, higher BMIs have been linked to poorer prognosis and more invasive
carcinoma at the time of detection.20 Recently there have been three well designed published
studies that have tried to establish a correlation among increases in BMI and SLNB procedural
outcomes. 2, 6, 13 Cox et al’s studied 1356 SNLB patients with mean BMI of 29.54 and an age
range of 20-81. Even though Cox’s study indicated that with an increase of one year or 1 unit of
BMI decrease the success rate by almost 5%, they concluded that there is only a general trend

which suggests a decrease in the success rate with increasing BMI and age, but this was not
found to have statistical significance. Therefore, it is suggested, but not confirmed, that SLNB
may be unsuccessful in this patient population6. However, Hughes et al who looked at a large
spectrum of BMIs similar to the Cox et al study (BMI of 18-54.1) with approximately equal
distribution between normal, overweight, and obese patients’ concluded that obesity alone does
not affect sentinel node identification or contribute to the false negative rate.2 In addition,
another study similar done by Derossis et al looked at BMI and age and concluded that SLNB
cannot be contraindicated in patients with increasing weight and age13.
Our study which looked at BMI of 30, which demarcates normal to overweight from
obese individuals, showed that obesity itself seems to be a significant variable that contributes to
failure of sentinel node mapping using both blue dye (methylene blue and lymphazurin). The
odds of success using blue dye in an obese patient were approximated to be 0.5 or almost a fifty
percent chance of failure, while the normal to overweight patient showed a higher success rate.
Our study’s Sentinel Node mapping failure rate seems to be at a higher rate and statistically
significant compared to Cox study. However, our study has less power. Further, our study
showed there is a significant effect on the failure of lymph mapping using technetium colloid.
However, the ability to palpate a sentinel node seem not be affected by obesity. While the
reported overall failure in sentinel lymph node detection approximately 1-2%, our study seem to
indicate it would be higher in obese patients.
It is unclear why failure increases with increasing BMI, but the increase adiposity might
contribute to slower lymphatic flow. This might be the reason why the obese patients have higher
failure rates in both blue dyes and technetium colloids. As our study’s trend indicate, as patients
BMI increase, a surgical oncologist must be aware that the chances of failure of both technetium

colloid and blue dye have a higher chance of failure with current practice guidelines. Therefore,
surgeon might want to consider employing other methods such as longer massage or more time
for lymph drainage to ensure lymph spread before interrogating for sentinel nodes. We anticipate
more reliable and increased success rates for sentinel lymph mapping will reduce morbidity
associated with sentinel node procedures.
Obesity alone might not contribute to failure of sentinel nodes because our study still
shows considerable failure rate even among normal to overweight category. Therefore, other
characteristics inherent to the patient might contribute to failure.
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Tables and Figures
Table 1: Patient Characteristics
Characteristic

Number

age ( 196 )
Age range

24 - 84

mean

55

median

56

Body mass index ( n = 197 )
BMI range

17 - 47

mean

29

median

29

White

102

(52%)

Hispanic

66

(33%)

Native American

15

(8%)

African American

10

(5%)

Other

5

(3%)

A

5

(5%)

B

22

(23%)

C

33

(34%)

D

25

(26%)

>D

7

(7%)

Breast Augmentation

1

(1%)

Pendulous breast

4

(4%)

I

89

(55%)

IIA

44

(27%)

Ethnicity ( n= 198 )

Bra Cup size ( n= 97 )*

Stage (n = 161)

*Bra cup size was not consistently reported

IIB

11

(7%)

IIIA

12

(7%)

IIIB

3

(2%)

IIIC

1

(1%)

IV

1

(1%)

Figure 1: Sentinel lymph identification method success and failure rates

Table 2: - Effect on odds ratio by patient BMI on various sentinel node detection methods
detection method

blue dye

Hot Node

Palpable node

Variable

odds ratio

95% confidence interval

BMI (continuous)

1.04

( 1.01 - 1.07 )

BMI 25

0.94

( 0.50 - 1.75 )

BMI 30

0.54

( 0.30 - 0.98 )

BMI (continuous)

0.97

( 0.89 - 1.03 )

BMI 25

0.26

( 0.06 - 1.16 )

BMI 30

0.32

( 0.11 - 0.93 )

BMI (continuous)

0.98

( 0.941 -1.02 )

BMI 25

0.82

( 0.45 - 1.50 )

BMI 30

0.71

( 0.41 - 1.25 )

